Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage
precision oncology company, today announced details relating to
eight abstracts being presented at the American Association for
Cancer Research (AACR) Annual Meeting 2023, taking place April
14-19 in Orlando, Florida.
“Prelude's six preclinical and two clinical abstracts being
presented at the AACR Annual Meeting highlight the important
progress we are making across our pipeline. Initial safety,
pharmacokinetic and pharmacodynamic profiles in solid tumors for
both PRT2527 and PRT1419 support continued development of both
compounds in hematological cancers,” said Jane Huang, M.D.,
President and Chief Medical Officer of Prelude.
“Additionally, we will be presenting preclinical data on our orally
bioavailable SMARCA2 degrader program for the first
time.”
“We are also presenting preclinical data for both our next
generation CDK4/6 inhibitor, PRT3645, and our SMARCA2 degrader,
PRT3789, in combination with other targeted therapies. These
studies demonstrate the favorable combinability of our compounds
with standard of care medicines and inform potential clinical
development,” added Peggy Scherle, Ph.D., Chief Scientific
Officer of Prelude.
Details of the clinical abstracts upcoming presentations
are as follows:
Title: A phase 1, open-label,
dose-escalation study of PRT1419, a selective induced myeloid
leukemia cell differentiation protein (MCL-1) inhibitor, in
patients (pts) with advanced/metastatic solid
tumorsPresenter: Gerald
Falchook Session Title: First-in-Human Phase
I Clinical Trials 2 Date and Time: Tuesday
April 18, 2023, 9:00 AM - 12:30 PM Location: Poster Section
45 Poster Board Number: 4 Abstract Presentation Number:
CT172
Title: A phase 1, open-label,
multicenter, dose-escalation study of PRT2527, a cyclin-dependent
kinase 9 (CDK9) inhibitor, in adult patients (pts) with advanced
solid tumors Presenter: Jason T.
Henry Session Title: First-in-Human Phase I
Clinical Trials 2 Date and Time: Tuesday
April 18, 2023 9:00 AM - 12:30 PM Location: Poster Section
45 Poster Board Number: 5 Abstract Presentation Number:
CT173
Details of the preclinical abstracts are as
follows:
Title: SMARCA2 (BRM) degraders promote
differentiation and inhibit proliferation in AML
models Presenter: Anjana
Agarwal Session Category: Experimental and
Molecular Therapeutics Session Title: New
Therapeutic Targeted Agents Date and Time:
Monday April 17, 2023 9:00 AM - 12:30 PM Location: Section
16 Poster Board Number: 17 Abstract Presentation Number:
1594
Title: Development of pharmacodynamic assays
for quantifying SMARCA2 protein degradation and target gene
expression in response to a SMARCA2 degrader
(PRT3789) Presenter: Andrew
Moore Session Category: Experimental and
Molecular Therapeutics Session Title:
Pharmacokinetics, Pharmacodynamics, and Molecular
Pharmacology Date and Time: Monday April 17,
2023 1:30 PM - 5:00 PM Location: Section 18 Poster Board
Number: 15 Abstract Presentation Number: 2792
Title: Combination therapy with selective
SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1)-deficient
cancers Presenter: Michael
Hulse Session Category: Experimental and
Molecular Therapeutics Session Title:
Epigenetics Date and Time: Wednesday April
19, 2023 9:00 AM - 12:30 PM Location: Section 20 Poster
Board Number: 8 Abstract Presentation Number: 6270
Title: The brain penetrant CDK4/6 Inhibitor,
PRT3645, is highly effective in combination with other targeted
therapies in preclinical models of NSCLC and HER2-positive breast
cancer Presenter: Yue
Zou Session Category: Molecular/Cellular
Biology and Genetics Session Title:
Cyclin-dependent Kinases and Cyclin-dependent Kinase
Inhibitors Date and Time: Wednesday April 19,
2023 9:00 AM - 12:30 PM Location: Section 9 Poster Board
Number: 2 Abstract Presentation Number: 5973
Title: MCL1 inhibitor PRT1419 demonstrates
anti-tumor activity in PBRM1-altered clear cell renal cancer and
synergizes with standard of care
agents Presenter: Norman
Fultang Session Category: Experimental and
Molecular Therapeutics Session Title: Cell
Death Pathways and Treatment / Molecular Classification of Tumors
for Diagnostics, Prognostics, and Therapeutic
Outcomes Date and Time: Wednesday April 19,
2023 9:00 AM - 12:30 PM Location: Section 16 Poster Board
Number: 9 Abstract Presentation Number: 6147
Title: Selective and orally bioavailable
SMARCA2 targeted degraders induce synthetic lethality in SMARCA4-
deficient solid tumor Presenter: Koichi
Ito Session Category: Experimental and
Molecular Therapeutics Session Title:
Epigenetics Date and Time: Wednesday April
19, 2023 9:00 AM - 12:30 PM Location: Section 20 Poster
Board Number: 15 Abstract Presentation Number: 6277
About Prelude
Therapeutics
Prelude Therapeutics is a clinical-stage precision oncology
company developing innovative drug candidates targeting critical
cancer cell pathways. The Company’s diverse pipeline is comprised
of highly differentiated, potentially best-in-class or
first-in-class proprietary small molecule compounds aimed at
addressing clinically validated pathways for cancers with
selectable underserved patients. Prelude’s pipeline includes four
candidates currently in clinical development: PRT1419, a potent,
selective inhibitor of MCL1, PRT2527, a potent and highly selective
CDK9 inhibitor, PRT3645, a next generation CDK4/6
inhibitor, and PRT3789, an IV administered, potent
and highly selective SMARCA2 degrader.
For more information, visit our website and follow us on
LinkedIn and Twitter.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995, including,
but not limited to, anticipated discovery, preclinical and clinical
development activities, timing of availability and announcements of
clinical results for Prelude’s product candidates, and the
potential benefits of Prelude’s product candidates . All statements
other than statements of historical fact are statements that could
be deemed forward-looking statements. Although Prelude believes
that the expectations reflected in such forward-looking statements
are reasonable, Prelude cannot guarantee future events, results,
actions, levels of activity, performance or achievements, and the
timing and results of biotechnology development and potential
regulatory approval is inherently uncertain. Forward-looking
statements are subject to risks and uncertainties that may cause
Prelude's actual activities or results to differ significantly from
those expressed in any forward-looking statement, including risks
and uncertainties related to Prelude's ability to advance its
product candidates, the receipt and timing of potential regulatory
designations, approvals and commercialization of product
candidates, the impact of the COVID-19 pandemic on Prelude’s
business, clinical trial sites, supply chain and manufacturing
facilities, Prelude’s ability to maintain and recognize the
benefits of certain designations received by product candidates,
the timing and results of preclinical and clinical trials,
Prelude's ability to fund development activities and achieve
development goals, Prelude's ability to protect intellectual
property, and other risks and uncertainties described under the
heading "Risk Factors" in documents Prelude files from time to time
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date of this press release, and
Prelude undertakes no obligation to revise or update any
forward-looking statements to reflect events or circumstances after
the date hereof.
Investor Contact: Lindsey
Trickett Vice President, Investor
Relations 240.543.7970 ltrickett@preludetx.com
Media Contact: Helen Shik Shik
Communications 617.510.4373
Helen@ShikCommunications.com
Prelude Therapeutics (NASDAQ:PRLD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Prelude Therapeutics (NASDAQ:PRLD)
Historical Stock Chart
From Apr 2023 to Apr 2024